The FDA recently approved corneal collagen cross-linking in the United States for the treatment of progressive keratoconus. This procedure now offers patients a treatment option aimed at targeting the underlying disease process and halting its progression, rather than just treating the symptoms commonly associated with keratoconus.
It is important for optometrists to understand how this treatment works, who would be considered candidates, what the procedure entails, and potential side effects of cross-linking, so that you can educate your patients on this exciting new technology.